3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
8
Leukemia, Myeloid, Acute
6
Neoplasm Metastasis
4
Leukemia, Myelomonocytic, Acute
4
Leukemia, Monocytic, Acute
4
Leukemia, Megakaryoblastic, Acute
4
Leukemia, Erythroblastic, Acute
4
Lung Neoplasms
3
Endometrial Neoplasms
3
Congenital Abnormalities
3
Colonic Neoplasms
3
Breast Neoplasms
3
Sarcoma
2
Oropharyngeal Neoplasms
2
Neuroblastoma
2
Melanoma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Eosinophilic, Acute
2
Leukemia, Basophilic, Acute
2
Leukemia
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Anus Neoplasms
2
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Stage I Mixed Cell Type Kidney Wilms Tumor
1
Interventions
Standard of Care
2
tocilizumab
1
selinexor
1
lenzilumab
1
cilgavimab and tixagevimab drug combination
1
Practice Guidelines as Topic
1
Observation
1
Interferon-alpha
1
Immunoglobulin G
1
IMM-101
1
Disulfides
1
CVnCoV COVID-19 vaccine
1
COVID-19 Vaccines
1
BNT162 Vaccine
1
Atorvastatin
1
2019-nCoV Vaccine mRNA-1273
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
COVID-19
×
Observation
×
Clear all
NCT04442048
2025-12-30
COV-IMMUNO
Canadian Cancer Trials Group
Phase 3
Completed
195 enrolled